Back to discover
Drug

Aceclofenac

Approved medicine
ClassCyclooxygenase-2 inhibitorResearchOngoing clinical research

Also known as Aceclofenaco, Aceclofenacum.

Prostaglandin G/H synthase 2
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Aceclofenac
Aliases & brands
AceclofenacoAceclofenacum
RxNorm CUI
16689
ChEMBL ID
CHEMBL93645
ATC codes
M01AB16M02AA25
UNII
RPK779R03H
Primary mechanism
Cyclooxygenase-2 inhibitor
Regulatory jurisdictions
mhra

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORCyclooxygenase-2 inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2015-01-22Safety communicationSafety
Drug Safety Update: Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2022
4
Late-stage (III+)
7
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 14Phase 2 / 32Phase 42

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.